Guangzhou Xinchuangyi Biomedical

Guangzhou Xinchuangyi Biomedical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the research and development of innovative ophthalmic drugs. The company focuses on utilizing recombinant protein technology to treat ocular surface diseases, including dry eye disease and corneal damage. Its core product, XCY-001, is a recombinant human lactoferrin eye drop that has entered Phase 2 clinical trials in China. By addressing the inflammatory and protective pathways of the eye, Xinchuangyi aims to establish a leading position in the high-growth ophthalmic biologics market. The company's pipeline also includes candidates for corneal repair and other vision-threatening conditions.